Drugs giant GlaxoSmithKline has reported positive results from an initial study into its development of a drug for HIV treatment.
ViiV Healthcare, a global HIV firm established by Glaxo and Pfizer, and Shionogi & Co announced this morning that the SPRING-2 (ING113086) - the Phase III study of the investigational integrase inhibitor dolutegravir in treatment-nave adults with HIV-1 - met its primary objective, showing non-inferiority of dolutegravir to raltegravir.
"The SPRING-2 findings indicate that once daily unboosted dolutegravir may offer people living with HIV an additional treatment option in the future," sid ViiV's Chief Medica Officer John Pottage.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"These are the first large-scale safety and efficacy data in nave patients, and we look forward to seeing further data in 2012 to build a more comprehensive picture of the role of dolutegravir," he said.
During a period of 48 weeks, 88% of study participants on the one-daily drug were "virologcially supressed" compared with 85% of participants on raltegravir (twice daily).
Shionogi & Co's Chief Executive Officer, Tsutae Nagata, said that the findings mark an "important milestone" for dolutegravir and the Shionogi-ViiV joint venture.
BC
-
What happens if you can’t pay your tax bill, and what is "Time to Pay"?Millions are due to file their tax return this Friday as the self-assessment deadline closes. Though the nightmare is not over until you pay the taxman what you owe - or face a penalty. But what happens if you can't afford to pay HMRC your tax bill, and what is "Time to Pay"?
-
What does Rachel Reeves’s plan for growth mean for UK investors?Rachel Reeves says she is going “further and faster” to kickstart the UK economy, but investors are unlikely to be persuaded
